⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RARE News
Ultragenyx Pharmaceutical Inc.
ROSEN, A RANKED AND LEADING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
globenewswire.com
RARE
LEVI & KORSINSKY, LLP: PHASE III CLINICAL TRIAL DESIGN AND ENDPOINT SELECTION AT CENTER OF ULTRAGENYX PHARMACEUTICAL SECURITIES LITIGATION
globenewswire.com
RARE
Ultragenyx Pharmaceutical Inc. Securities Class Action Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law
globenewswire.com
RARE
Form 8-K
sec.gov
RARE
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
globenewswire.com
RARE
RARE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
RARE
Pomerantz LLP Calls Attention to Class Action Against Ultragenyx Pharmaceutical Inc. – RARE
accessnewswire.com
RARE
Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE
prnewswire.com
RARE
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
prnewswire.com
RARE
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE
accessnewswire.com
RARE